Open Access

CX3CL1/fractalkine enhances prostate cancer spinal metastasis by activating the Src/FAK pathway

  • Authors:
    • Peng Liu
    • Yun Liang
    • Libo Jiang
    • Houlei Wang
    • Shengxing Wang
    • Jian Dong
  • View Affiliations

  • Published online on: July 18, 2018     https://doi.org/10.3892/ijo.2018.4487
  • Pages: 1544-1556
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chemokines serve important roles in the development of cancer. C-X3-C motif chemokine ligand 1 (CX3CL1) has been demonstrated to promote metastases in different types of tumors. The authors' previous studies demonstrated that the CX3CL1 (also termed fractalkine)/steroid receptor coactivator (Src)/focal adhesion kinase (FAK) signaling pathway is associated with spinal metastasis. In the present study, it was observed that CX3CL1/C-X3-C motif chemokine receptor 1 (CX3CR1) was overexpressed in prostate cancer tissues with spinal metastasis compared with primary tumors. Overexpression of CX3CR1 induced cell proliferation, migration and invasion, and inhibited cellular apoptosis. However, repression of CX3CR1 reduced cell proliferation, migration and invasion, and increased cellular apoptosis. In addition, the Src/FAK pathway was activated by CX3CL1, which depends on the Tyr992 residue of epidermal growth factor receptor (EGFR) for phosphorylation. The inhibitors of these kinases repressed the cell migration induced by CX3CL1 or CX3CR1 overexpression. Furthermore, overexpression of CX3CR1 induced the spinal metastasis of prostate cancer in an in vivo mouse model. Therefore, CX3CL1 and its regulation of the EGFR, Src and FAK pathways may be potential targets for the early prevention of spinal metastasis in prostate cancer.

References

1 

Aaron AD: The management of cancer metastatic to bone. JAMA. 272:1206–1209. 1994. View Article : Google Scholar : PubMed/NCBI

2 

Dominguez DE, Lauper N, Velastegui A and Reynolds J: Surgical management of the spinal metastases. Rev Med Suisse. 12:2168–2171. 2016.In French.

3 

Wu AS and Fourney DR: Evolution of treatment for metastatic spine disease. Neurosurg Clin N Am. 15:401–411. 2004. View Article : Google Scholar : PubMed/NCBI

4 

Dushyanthen S, Cossigny DA and Quan GM: The osteoblastic and osteoclastic interactions in spinal metastases secondary to prostate cancer. Cancer Growth Metastasis. 6:61–80. 2013. View Article : Google Scholar : PubMed/NCBI

5 

Choi D, Crockard A, Bunger C, Harms J, Kawahara N, Mazel C, Melcher R and Tomita K; Global Spine Tumor Study Group: Review of metastatic spine tumour classification and indications for surgery: the consensus statement of the Global Spine Tumour Study Group. Eur Spine J. 19:215–222. 2010. View Article : Google Scholar :

6 

Muralidharan A and Smith MT: Pathobiology and management of prostate cancer-induced bone pain: Recent insights and future treatments. Inflammopharmacology. 21:339–363. 2013. View Article : Google Scholar : PubMed/NCBI

7 

Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66. 2007. View Article : Google Scholar : PubMed/NCBI

8 

Przybyla BD, Shafirstein G, Vishal SJ, Dennis RA and Griffin RJ: Molecular changes in bone marrow, tumor and serum after conductive ablation of murine 4T1 breast carcinoma. Int J Oncol. 44:600–608. 2014. View Article : Google Scholar :

9 

Salazar N, Castellan M, Shirodkar SS and Lokeshwar BL: Chemokines and chemokine receptors as promoters of prostate cancer growth and progression. Crit Rev Eukaryot Gene Expr. 23:77–91. 2013. View Article : Google Scholar : PubMed/NCBI

10 

Liao YX, Zhou CH, Zeng H, Zuo DQ, Wang ZY, Yin F, Hua YQ and Cai ZD: The role of the CXCL12-CXCR4/CXCR7 axis in the progression and metastasis of bone sarcomas (Review). Int J Mol Med. 32:1239–1246. 2013. View Article : Google Scholar : PubMed/NCBI

11 

Liu JF, Tsao YT and Hou CH: Fractalkine/CX3CL1 induced intercellular adhesion molecule-1-dependent tumor metastasis through the CX3CR1/PI3K/Akt/NF-κB pathway in human osteosarcoma. Oncotarget. 8:54136–54148. 2016.

12 

Tardáguila M, Mira E, García-Cabezas MA, Feijoo AM, Quintela-Fandino M, Azcoitia I, Lira SA and Mañes S: CX3CL1 promotes breast cancer via transactivation of the EGF pathway. Cancer Res. 73:4461–4473. 2013. View Article : Google Scholar : PubMed/NCBI

13 

Tang J, Xiao L, Cui R, Li D, Zheng X, Zhu L, Sun H, Pan Y, Du Y and Yu X: CX3CL1 increases invasiveness and metastasis by promoting epithelial-to-mesenchymal transition through the TACE/TGF-α/EGFR pathway in hypoxic androgen-independent prostate cancer cells. Oncol Rep. 35:1153–1162. 2016. View Article : Google Scholar : PubMed/NCBI

14 

Ferretti E, Pistoia V and Corcione A: Role of fractalkine/CX3CL1 and its receptor in the pathogenesis of inflammatory and malignant diseases with emphasis on B cell malignancies. Mediators Inflamm. 2014:4809412014. View Article : Google Scholar : PubMed/NCBI

15 

Shulby SA, Dolloff NG, Stearns ME, Meucci O and Fatatis A: CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res. 64:4693–4698. 2004. View Article : Google Scholar : PubMed/NCBI

16 

Jamieson WL, Shimizu S, D'Ambrosio JA, Meucci O and Fatatis A: CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: Potential role in prostate cancer bone tropism. Cancer Res. 68:1715–1722. 2008. View Article : Google Scholar : PubMed/NCBI

17 

Liu W, Bian C, Liang Y, Jiang L, Qian C and Dong J: CX3CL1: A potential chemokine widely involved in the process spinal metastases. Oncotarget. 8:15213–15219. 2017.PubMed/NCBI

18 

Wiemer AJ, Wernimont SA, Cung TD, Bennin DA, Beggs HE and Huttenlocher A: The focal adhesion kinase inhibitor PF-562,271 impairs primary CD4+ T cell activation. Biochem Pharmacol. 86:770–781. 2013. View Article : Google Scholar : PubMed/NCBI

19 

Yu W, He X, Ni Y, Ngeow J and Eng C: Cowden syndrome-associated germline SDHD variants alter PTEN nuclear translocation through SRC-induced PTEN oxidation. Hum Mol Genet. 24:142–153. 2015. View Article : Google Scholar

20 

Lee BY, Hochgräfe F, Lin HM, Castillo L, Wu J, Raftery MJ, Martin Shreeve S, Horvath LG and Daly RJ: Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer. Mol Cancer Ther. 13:190–201. 2014. View Article : Google Scholar

21 

Rabbani SA, Valentino ML, Arakelian A, Ali S and Boschelli F: SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis. Mol Cancer Ther. 9:1147–1157. 2010. View Article : Google Scholar : PubMed/NCBI

22 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-DeltaDeltaC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar

23 

Li HY, Cui XY, Wu W, Yu FY, Yao HR, Liu Q, Song EW and Chen JQ: Pyk2 and Src mediate signaling to CCL18-induced breast cancer metastasis. J Cell Biochem. 115:596–603. 2014. View Article : Google Scholar

24 

Sarabia-Estrada R, Zadnik PL, Molina CA, Jimenez-Estrada I, Groves ML, Gokaslan ZL, Bydon A, Witham TF, Wolinsky JP and Sciubba DM: A rat model of metastatic spinal cord compression using human prostate adenocarcinoma: Histopathological and functional analysis. Spine J. 13:1597–1606. 2013. View Article : Google Scholar : PubMed/NCBI

25 

Sun Y, Wang F, Sun X, Wang X, Zhang L and Li Y: CX3CR1 regulates osteoarthrosis chondrocyte proliferation and apoptosis via Wnt/beta-catenin signaling. Biomed Pharmacother. 96:1317–1323. 2017. View Article : Google Scholar : PubMed/NCBI

26 

Wang H, Cai J, Du S, Guo Z, Xin B, Wang J, Wei W and Shen X: Fractalkine/CX3CR1 induces apoptosis resistance and proliferation through the activation of the AKT/NF-κB cascade in pancreatic cancer cells. Cell Biochem Funct. 35:315–326. 2017. View Article : Google Scholar : PubMed/NCBI

27 

Luo W, Lin Y, Meng S, Guo Y, Zhang J and Zhang W: miRNA-296-3p modulates chemosensitivity of lung cancer cells by targeting CX3CR1. Am J Transl Res. 8:1848–1856. 2016.PubMed/NCBI

28 

Yao X, Qi L, Chen X, Du J, Zhang Z and Liu S: Expression of CX3CR1 associates with cellular migration, metastasis, and prognosis in human clear cell renal cell carcinoma. Urol Oncol. 32:162–170. 2014. View Article : Google Scholar

29 

Xu Z, Zheng X, Yang L, Liu F, Zhang E, Duan W, Bai S, Safdar J, Li Z and Sun C: Chemokine receptor 7 promotes tumor migration and invasiveness via the RhoA/ROCK pathway in metastatic squamous cell carcinoma of the head and neck. Oncol Rep. 33:849–855. 2015. View Article : Google Scholar

30 

Lv Z, Hu M, Ren X, Fan M, Zhen J, Chen L, Lin J, Ding N, Wang Q and Wang R: Fyn mediates high glucose-induced actin cytoskeleton reorganization of podocytes via promoting ROCK activation in vitro. J Diabetes Res. 2016:56718032016. View Article : Google Scholar : PubMed/NCBI

31 

Hamaguchi M, Yamagata S, Thant AA, Xiao H, Iwata H, Mazaki T and Hanafusa H: Augmentation of metalloproteinase (gelatinase) activity secreted from Rous sarcoma virus-infected cells correlates with transforming activity of src. Oncogene. 10:1037–1043. 1995.PubMed/NCBI

32 

Hunter T: A tail of two src's: Mutatis mutandis. Cell. 49:1–4. 1987. View Article : Google Scholar : PubMed/NCBI

33 

Parsons JT, Martin KH, Slack JK, Taylor JM and Weed SA: Focal adhesion kinase: A regulator of focal adhesion dynamics and cell movement. Oncogene. 19:5606–5613. 2000. View Article : Google Scholar : PubMed/NCBI

34 

Figel S and Gelman IH: Focal adhesion kinase controls prostate cancer progression via intrinsic kinase and scaffolding functions. Anticancer Agents Med Chem. 11:607–616. 2011. View Article : Google Scholar : PubMed/NCBI

35 

Rentala S, Chintala R, Guda M, Chintala M, Komarraju AL and Mangamoori LN: Atorvastatin inhibited Rho-associated kinase 1 (ROCK1) and focal adhesion kinase (FAK) mediated adhesion and differentiation of CD133+CD44+ prostate cancer stem cells. Biochem Biophys Res Commun. 441:586–592. 2013. View Article : Google Scholar : PubMed/NCBI

36 

Schlaepfer DD, Hanks SK, Hunter T and van der Geer P: Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature. 372:786–791. 1994. View Article : Google Scholar : PubMed/NCBI

37 

Jin JK, Dayyani F and Gallick GE: Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer. 128:2545–2561. 2011. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

October 2018
Volume 53 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liu, P., Liang, Y., Jiang, L., Wang, H., Wang, S., & Dong, J. (2018). CX3CL1/fractalkine enhances prostate cancer spinal metastasis by activating the Src/FAK pathway. International Journal of Oncology, 53, 1544-1556. https://doi.org/10.3892/ijo.2018.4487
MLA
Liu, P., Liang, Y., Jiang, L., Wang, H., Wang, S., Dong, J."CX3CL1/fractalkine enhances prostate cancer spinal metastasis by activating the Src/FAK pathway". International Journal of Oncology 53.4 (2018): 1544-1556.
Chicago
Liu, P., Liang, Y., Jiang, L., Wang, H., Wang, S., Dong, J."CX3CL1/fractalkine enhances prostate cancer spinal metastasis by activating the Src/FAK pathway". International Journal of Oncology 53, no. 4 (2018): 1544-1556. https://doi.org/10.3892/ijo.2018.4487